Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of Entacapone tablets, which will enhance the company's product portfolio and competitive strength in the pharmaceutical market [1] Group 1: Product Approval - The company has obtained the drug registration certificate for Entacapone tablets, which can be used as an adjunct therapy for Parkinson's disease when standard medications are insufficient [1] - Entacapone tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] Group 2: Market Potential - The estimated sales revenue for Entacapone tablets in Chinese public medical institutions is approximately RMB 286 million in 2024 [1] - The approval of Entacapone tablets will further enrich the company's formulation product series, contributing to an increase in overall competitiveness [1]

Group 1 - The company has received a drug registration certificate from the National Medical Products Administration for Ibuprofen Tablets, which will be classified as a Class A over-the-counter drug [1][3]. - The drug is indicated for the relief of mild to moderate pain such as headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, as well as for fever caused by common colds or influenza [2]. - The approval of Ibuprofen Tablets enhances the company's analgesic product line, potentially benefiting more patients and expanding market sales, which is expected to have a positive impact on the company's operating performance [3]. Group 2 - The company emphasizes the importance of drug research and development, maintaining strict quality and safety controls throughout the drug development, manufacturing, and sales processes [3]. - Future market sales of the product may be influenced by various uncertain factors, including policy environment and market changes [3].

Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for the registration of an inhalation solution containing ipratropium bromide, which will enhance the company's product line and positively impact its development [1] Group 1 - The company has obtained a drug registration certificate for the inhalation solution [1] - This new product is expected to enrich the company's product offerings [1] - The approval is seen as a positive development for the company's growth [1]

Core Viewpoint - Chengda Biological (688739.SH) announced that its wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., has recently received the Drug Registration Certificate for the lyophilized human rabies vaccine (human diploid cells) from the National Medical Products Administration [1] Group 1 - The company has successfully obtained regulatory approval for its human diploid rabies vaccine, which is a significant milestone in its product development [1] - The approval indicates the company's commitment to expanding its vaccine portfolio and enhancing its market presence in the biopharmaceutical industry [1]

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. has received the drug registration certificate for Mecobalamin Tablets from the National Medical Products Administration, marking a significant advancement in the company's product portfolio for the treatment of peripheral neuropathy [1][2][3]. Group 1: Basic Information - Drug Name: Mecobalamin Tablets [1] - Acceptance Number: CYHS2402791 [1] - Certificate Number: 2026S00402 [1] - Dosage Form: Tablet [1] - Packaging Specification: 10 tablets/board × 2 boards/box [1] - Registration Classification: Class 4 Chemical Drug [1] - Drug Registration Standard Number: YBH01362026 [1] - License Holder: Hubei Guangji Pharmaceutical Co., Ltd. [1] - Production Company: Hubei Guangji Pharmaceutical Co., Ltd. [1] - Approval Conclusion: The product meets the requirements for drug registration and has been approved for registration [1]. Group 2: Drug Application - Mecobalamin Tablets are primarily indicated for the treatment of peripheral neuropathy [2]. Group 3: Impact on the Company - The approval of the Mecobalamin Tablets registration certificate signifies an important development in the company's product layout for treating peripheral nerve diseases, providing high-quality domestic drug options for patients [3]. - The company aims to uphold the principle of "quality first, service health" and will fully promote the production and market supply of this product to benefit a wide range of patients [3].

Core Viewpoint - The company has received a drug registration certificate for Tadalafil Tablets (20mg) from the Food and Drugs Authority of Ghana, allowing for legal sales in the country, which supports the company's international market expansion efforts [1] Group 1: Product Approval - The drug Tadalafil (20mg) is classified as a PDE5 inhibitor, used for treating erectile dysfunction and symptoms of benign prostatic hyperplasia [1] - The approval marks a significant step for the company in establishing a presence in the Ghanaian market [1] Group 2: Market Impact - Currently, there is no established sales for Tadalafil in Ghana, and even with potential sales, the revenue contribution is expected to be low relative to the company's overall revenue [1] - The acquisition of the drug registration certificate is not anticipated to have a significant impact on the company's near-term operating performance [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Glucosamine Sulfate Capsules, which are primarily used for treating primary and secondary osteoarthritis [1] Group 1: Product Approval - The approval of Glucosamine Sulfate Capsules enhances the company's formulation product portfolio [1] - This product is classified as a Category B item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) [1] Group 2: Market Potential - The estimated sales revenue for Glucosamine Sulfate Capsules in Chinese public medical institutions is approximately RMB 850 million in 2024 [1] - The introduction of this product is expected to improve the company's overall competitiveness in the market [1] Group 3: Industry Considerations - The pharmaceutical sales business is subject to uncertainties influenced by industry policies and market conditions [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial registration of human thrombin from the National Medical Products Administration [1] Group 1: Regulatory Approval - The National Medical Products Administration has reviewed and accepted the drug registration application based on Article 32 of the Administrative Licensing Law of the People's Republic of China [1] - The human thrombin is indicated for external use only, aimed at controlling minor bleeding from capillaries and small veins when standard surgical techniques are ineffective or impractical [1] Group 2: Product Usage - The product can be used in conjunction with absorbable gelatin sponges for enhanced hemostatic effect [1]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Lidocaine Hydrochloride Gel from the National Medical Products Administration, marking a significant milestone in the company's product development and regulatory compliance [1][4]. Group 1: Drug Registration Certificate Details - The Drug Registration Certificate pertains to Lidocaine Hydrochloride Gel, which is indicated for local anesthesia during procedures requiring such intervention [1]. - The company is one of three domestic enterprises that have obtained this Drug Registration Certificate for the product [1]. - The estimated sales revenue for Lidocaine Hydrochloride Gel in national secondary hospitals and above is approximately 40.86 million yuan in 2024 [1]. Group 2: R&D Investment and Production Approval - As of the announcement date, the cumulative R&D investment for this project is approximately 7.27 million yuan (unaudited) [2]. - This is the first production license obtained by the company in 2026 [3]. Group 3: Impact on the Company - The acquisition of the Drug Registration Certificate for Lidocaine Hydrochloride Gel enhances the company's product line and is expected to improve its market competitiveness [4]. - The impact of this certificate on the company's near-term operating performance is not anticipated to be significant [4].

General Principles - The regulation is established based on the Drug Administration Law of the People's Republic of China, emphasizing public health and adherence to scientific and ethical principles [1] - The government aims to enhance the drug innovation system, supporting clinical value-oriented drug research and innovation, and promoting the development of traditional Chinese medicine [1] Drug Research and Registration - Drug research activities must comply with non-clinical and clinical trial quality management standards, ensuring data integrity and traceability [3] - Non-clinical safety evaluation studies must be conducted by qualified institutions, with a decision on qualification applications made within 20 working days [6] - Clinical trial sponsors must select capable institutions and researchers, ensuring participant protection and data management [8] Drug Production - Drug production activities require an application to the provincial drug supervision department, with a decision made within 30 working days [19] - Drug production licenses are valid for five years, and renewal applications must be submitted before expiration [19] Drug Operation - Drug operating enterprises must apply for licenses, with a decision made within 20 working days [28] - Drug operating licenses are also valid for five years, requiring renewal for continued operation [28] Drug Quality Management - Drug quality standards must align with national standards, and any necessary revisions must be reported to the drug supervision department [11] - The government supports the development of drug quality assurance systems and encourages monitoring of adverse drug reactions [15] Market Exclusivity - New pediatric drugs and treatments for rare diseases may receive market exclusivity for up to two years and seven years, respectively, under certain conditions [21][12] - The specific conditions for market exclusivity will be determined by the drug supervision department [13] Supervision and Management - Drug supervision departments have the authority to conduct inspections and enforce compliance, including the ability to seize products that may harm public health [41] - A unified traceability standard for drugs will be established to ensure accountability throughout the supply chain [66] Legal Responsibilities - Violations of the regulations can result in significant fines, including penalties for the sale of unapproved drugs and unauthorized production practices [50][51]